Please login to the form below

Not currently logged in

Pfizer CEO reckons rebates will disappear, and that’s a positive

The move also has the support of FDA Commissioner Scott Gottlieb

Pfizer’s chief executive Ian Read (pictured below) has said that he expects drug price rebates will eventually disappear in the US, and that could give drugs like arthritis drug Xeljanz and biosimilars a lift.

Ian Read

Speaking on the company’s second-quarter results call, he said that eliminating rebates – one of the main themes of President Donald Trump’s blueprint for reducing drug pricing – would be a positive for the pharma industry overall.

That is because it would do away with what is known as the ‘rebate trap’, where access to a new and innovative products is restricted because an incumbent product on a formulary is offering a large rebate – something that Read says directly affected JAK inhibitor Xeljanz (tofacitinib) and slowed its take-up in the market.

“At the moment in time, about 40% of pharmaceutical prices are subsidies to the rest of the health care system. We realise some 58% of our list price. The rest goes to subsidise profitability of [pharmacy benefit managers], insurance companies and frankly premiums for those that are healthy.”

“This is not a sustainable position, and so removal of the rebates I believe will be very beneficial to patients and our industry, especially those companies … who are launching new products over the next five years or so.”

Abandoning rebates could deliver a situation where drug prices fluctuate in line with healthcare inflation – and that shouldn’t affect Pfizer’s sales growth predictions, said Read. And while he wouldn’t be drawn on how quickly a rebate-free market could be created, he did say that discussions with Trump revealed a “huge sense of urgency” to act on the issue.

The move also has the support of FDA Commissioner Scott Gottlieb (pictured below), who said in May that removing the so-called ‘safe harbour’ for drug rebates under the Anti-Kickback Statute – which makes it illegal to pay an incentive for drugs or services covered by Medicare, Medicaid or other federal healthcare programmes – would “restore some semblance of reality to the relationship between list and negotiated prices, and thereby boost affordability and competition”.

Scott Gottlieb

Kickback will come of course from PBMs – including Express Scripts, CVS Caremark and UnitedHealth – as well as insurers who argue that rebates are a diversion and that their negotiating tactics have kept overall drug costs in check. And some analysts say that as some PBMs already pass on 100% of rebates, the move could actually increase plan premiums.

Read’s comments came shortly after Pfizer’s much publicised decision not to go ahead with planned mid-year price increases after being called out publicly by Trump. In an interview with CNBC, Read said that the decision was taken to defer price increases ahead of the conversation with Trump “because we wanted to have a positive relationship with the Hill and administration as we go through this blueprint”.

The discussion over rebates and the future of drug pricing came amid a healthy set of figures for Pfizer, which reported an 4% increase in revenues to $13.5bn, driven by its innovative health unit and particularly Xeljanz – up 38% to $463m in the quarter – as well as breast cancer drug Ibrance (palbociclib) which rose 20% to $1bn and novel oral anticoagulant Eliquis (apixaban), which rocketed 47% to $889m.

Article by
Phil Taylor

1st August 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....